文献速递静脉血栓栓塞慢性静脉疾病

靶向α6β1整合素信号:普仑司特调节静脉内皮功能并减轻血栓后静脉壁损伤

Targeting α6β1 integrin signaling with pranlukast to modulate venous endothelium function and reduce post-thrombotic vein wall injury.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2026-09-04

该临床前研究在小鼠深静脉血栓模型中发现,层粘连蛋白及其受体α6β1整合素在血栓后静脉壁高表达至21天。普仑司特(PLK)抑制α6β1整合素可减少静脉壁α6和β1整合素水平、降低静脉壁厚度和促炎单核细胞(CCR2+),且不影响血栓形成,提示其作为非抗凝策略预防血栓后综合征的潜力。

要点

  • 层粘连蛋白-α6β1整合素轴在血栓后静脉壁高表达,是潜在治疗靶点。
  • 普仑司特减轻静脉壁厚度和CCR2+促炎单核细胞,不改变血栓形成。
  • 靶向α6β1整合素可能成为预防血栓后综合征的非抗凝策略。

核心结论

  • 靶向α6β1整合素可减轻实验性深静脉血栓后的静脉壁纤维化损伤,且不改变血栓形成。

研究设计与样本

  • 临床前研究:C57BL/6小鼠行下腔静脉结扎,表征细胞外基质蛋白,并在体外和体内测试普仑司特。

主要发现

  • 血栓后下腔静脉中 layer 粘连蛋白、纤维蛋白、血栓调节蛋白和纤连蛋白存在,层粘连蛋白及α6β1整合素高表达至21天。
  • 体外普仑司特处理24小时显著降低Itga6、Itgb1和sele转录。
  • 普仑司特组血栓重量和长度与对照组相当,表明不影响血栓形成。

临床怎么用

  • 普仑司特作为α6β1整合素拮抗剂,可能用于预防血栓后综合征,但需进一步慢性模型和转化研究验证。

局限性

  • 研究为临床前小鼠模型,结论需在慢性模型和转化研究中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Post-thrombotic syndrome (PTS) develops in 20% to 50% of patients following deep vein thrombosis (DVT) due to persistent vein wall injury, inflammation, and fibrotic remodeling. Current anticoagulant therapies do not directly address PTS pathogenesis and carry bleeding risks. We characterized the extracellular matrix (ECM) components and evaluated whether pharmacological inhibition of α6β1 integrin with pranlukast (PLK) could modulate post-thrombotic vein wall injury in a preclinical DVT model. METHODS: ECM protein composition was characterized in C57BL/6 mice by Western blotting of inferior vena cava (IVC) harvested after IVC ligation from 4 to 21 days, identifying the laminin-α6β1 integrin axis as a therapeutic target. The presence of α6β1 was confirmed via immunofluorescence in post-thrombotic mice up to 21 days. PLK, a candidate α6β1 integrin antagonist, was tested in vitro and in vivo. Venous endothelial cells were treated with PLK to assess transcription of integrins (Itga6 and Itgb1) and inflammation markers (sele). In vivo, C57BL/6 mice received PLK or vehicle before and after IVC ligation. Thrombus characteristics, vein wall remodeling, integrin protein expression, and cellular composition were evaluated. RESULTS: Laminin, fibrin, thrombomodulin, and fibronectin were present in the post-thrombotic IVC in mice. The ECM protein laminin and its primary receptor, α6β1 integrin (CD49f/CD29), were highly expressed up to 21 days post-thrombosis in the vein wall. In vitro, PLK treatment significantly decreased transcription of Itga6, Itgb1, and sele after 24 hours. PLK did not affect thrombus formation, with comparable thrombus weights and lengths across groups, demonstrating a safety profile. The administration of PLK was associated with decreased levels of α6 and β1 integrins in the vein wall and thrombus, as well as a significant reduction in vein wall thickness (PLK, 44.95 ±5.09 μm; dimethyl sulfoxide, 56.84 ±6.54 μm; P = .0081) at 8 days and in proinflammatory monocytes (CCR2+) compared with control (PLK, 14.73 ±1.69; dimethyl sulfoxide, 23.15 ± 2.38; P < .0001). CONCLUSIONS: This study demonstrates that targeting α6β1 integrin with PLK reduces vein wall fibrotic injury following experimental DVT without altering thrombus formation. These findings identify a novel, nonanticoagulant therapeutic strategy for PTS prevention that warrants further investigation in chronic models and translational studies.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Taylor AL, Moreno O, Luke CE, et al. Targeting α6β1 integrin signaling with pranlukast to modulate venous endothelium function and reduce post-thrombotic vein wall injury. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42697433. doi:10.1016/j.jvsv.2026.102615

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。